133 The 31-gene expression profile test stratifies recurrence-free and melanoma-specific survival in patients with stage IB-IIA and stage IIB cutaneous melanoma

Abstract

BackgroundPatients with stage IB-IIA cutaneous melanoma (CM) account for approximately one quarter of all patients with melanoma, have 20–38% recurrence rates, and 6–12% melanoma-specific mortality rates by 10 years,1 2...